|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Argos Therapeutics, Inc. And DC Bio Corp. Announce New Clinical Trial To Begin For Chronic Lymphocytic Leukemia
11/8/2005
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 8, 2005--Immunotherapy pioneer Argos Therapeutics in conjunction with Toronto-based DC Bio Corp., announced that a clinical trial for chronic lymphocytic leukemia (CLL) is scheduled to begin in Q1 2006 using Argos's proprietary RNA-loaded dendritic cell vaccine technology. The investigator-sponsored Phase I/II study will be conducted at McMaster University in Hamilton, Ontario, Canada, by Graeme Fraser, M.D., F.R.C.P.C. McMaster University received a $573,000 grant from the Ontario Cancer Research Network (OCRN) to conduct the clinical trial.
|
|
|
|
|
|
|
|
|
|
|
|